[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538271":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":18,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":18,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Huashan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"aSAH treatment based on Intraventricular ICP monitoring","EXPERIMENTAL","In the acute phase of aSAH (following endovascular or craniotomy occlusion of the aneurysm), a ventricular ICP monitoring probe is surgically implanted. And the postoperative management of ICP is guided by quantifiable ICP parameters. The remaining treatments are consistent with those in the control group.",[13],"Device: Intraventricular intracranial pressure monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"aSAH treatment without Intraventricular ICP monitoring","NO_INTERVENTION","Only aSAH treatment surgery is performed without intraventricular ICP monitoring probe implantation. The treatment is not guided by ICP monitoring, and instead, aSAH treatment is conducted based on clinical signs and CT imaging to assess ICP.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","Intraventricular intracranial pressure monitoring","The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.",[9],[26,30],{"name":27,"affiliation":28,"role":29},"Wei Zhu, Ph.D.","Department of Neurosurgery, Huashan Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"Xuehai Wu, Ph.D.",[33],{"name":31,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","+8613764880571","Wuxuehai2013@163.com",[38],{"facility":28,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],121.45806,31.22222,{"lat":49,"lon":48},[52],{"name":31,"role":34,"phone":35,"phoneExt":18,"email":53},"wuxuehai2013@163.com",{"type":29,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Wei Zhu","Vice director of neurosurgery department, Huashan Hospital, Fudan University","100538271","asah-treatment-based-on-intraventricular-icp-monitoring-a-prospective-multicenter-randomized-and-controlled-trial-100538271",false,"NCT06288659","aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial","Aneurysmal Subarachnoid Hemorrhage Treatment Based on Intraventricular Intracranial Pressure Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial","ASTIM-MT","Inclusion Criteria:\n\n* Confirmed diagnosis of aSAH: presence of SAH symptoms, confirmed by CT scan or lumbar puncture. CTA or DSA confirms ruptured intracranial aneurysm (IA) as the cause. Decision made to perform craniotomy clipping or endovascular treatment within 72 hours aiming for a single procedure to cure the bleeding artery aneurysm;\n* Age ≥ 18 years;\n* The onset of symptoms should occur within 72 hours;\n* The Hunt-Hess grade is between 2 and 4, and the CT imaging findings correspond to a modified Fisher grade of 2 to 4.\n* Obtain the consent of the patient and their family members, and have them sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy or lactation period;\n* Patients presenting with bilateral dilated pupils upon admission;\n* Patients with concurrent tumors, hemorrhagic diseases, or other severe underlying conditions (such as chronic obstructive pulmonary disease, multiple organ dysfunction syndrome, severe diabetes mellitus, congestive heart failure, and chronic kidney disease);\n* Patients with a history of brain disorders or previous brain surgeries;\n* Hemorrhage attributable to causes other than aneurysm;\n* Aneurysmal rupture bleeding concurrent with moyamoya disease;\n* Other underlying conditions that impact prognosis;\n* Patients volunteering for ICP monitoring;\n* Participants in other ongoing clinical trails;\n* Other circumstances deemed inappropriate for inclusion (to be determined by two physicians).","ALL","18 Years",{"count":68,"type":69},372,"ESTIMATED","INTERVENTIONAL",[72],"NA","ASTIM is a multicenter, prospective, randomised, blinded end-point assessed trial, to investigate the efficacy and safety of treatment based on intracranial pressure monitoring in improving the prognosis of patients with aneurysmal subarachnoid hemorrhage.",[75,76],"Aneurysmal Subarachnoid Hemorrhage","Intracranial Pressure Increase",[78,22,79],"Aneurysmal subarachnoid hemorrhage","Multicenter randomized clinical trail","2025-01-04",{"date":82,"type":83},"2025-01-07","ACTUAL",{"date":85,"type":83},"2024-05-20",{"date":87,"type":69},"2026-12-30",{"name":5,"class":6},1]